Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Gastroenterology ; 136(2): 673-82.e1, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19027011

RESUMEN

BACKGROUND & AIMS: We tested the hypothesis that oral administration of bile salts, which are known to increase the biliary excretion of unconjugated bilirubin (UCB), decreases unconjugated hyperbilirubinemia in the Gunn rat model. METHODS: Adult Gunn rats were fed a standard diet or the same diet supplemented with 0.5 weight % ursodeoxycholic acid (UDCA) or cholic acid (CA) for 1 or 6 weeks. UCB and urobilinoids, a family of intestinal UCB breakdown products, were determined in plasma, feces, or both. After 6 weeks of treatment, tracer 3H-UCB was administered intravenously to determine steady-state UCB kinetics over the next 60 hours. RESULTS: One-week treatment with UDCA or CA decreased plasma UCB concentrations by 21% and 30%, respectively (each P < .01). During the first 4 days of treatment, both UDCA and CA increased the combined fecal excretion of UCB and urobilinoids (+52% and +32%, respectively; each P < .01). Prolongation of treatment to 6 weeks caused a persistent decrease in plasma UCB concentrations to approximately 40% below baseline (each bile salt P < .001). (3)H-UCB kinetic studies showed that UDCA and CA administration decreased UCB pool size (-33% and -32%, respectively; each P < .05) and increased UCB fractional turnover (+33% and +25%, respectively; each P < .05). CONCLUSIONS: Dietary bile salt administration induces a large, persistent decrease in plasma UCB concentrations in Gunn rats. Both UDCA and CA enhance UCB turnover by increasing its fecal disposal. These results support the application of oral bile salt treatment in patients with unconjugated hyperbilirubinemia.


Asunto(s)
Ácidos y Sales Biliares/uso terapéutico , Fármacos Gastrointestinales/uso terapéutico , Hiperbilirrubinemia/tratamiento farmacológico , Administración Oral , Animales , Ácidos y Sales Biliares/administración & dosificación , Bilirrubina/metabolismo , Ácido Cólico/administración & dosificación , Ácido Cólico/uso terapéutico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Heces , Fármacos Gastrointestinales/administración & dosificación , Hiperbilirrubinemia/metabolismo , Masculino , Ratas , Tritio , Ácido Ursodesoxicólico/administración & dosificación , Ácido Ursodesoxicólico/uso terapéutico
2.
Pediatr Res ; 62(6): 725-30, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17957158

RESUMEN

Unconjugated hyperbilirubinemia in Crigler-Najjar (CN) disease is conventionally treated with phototherapy and phenobarbital. Orlistat treatment increases fecal fat excretion and decreases plasma unconjugated bilirubin (UCB) concentrations in Gunn rats, the animal model for CN disease. We determined in CN patients the effects of orlistat treatment on plasma UCB concentrations, and on fecal excretion of fat and UCB. A randomized, placebo-controlled, double-blind, cross-over trial was conducted in 16 patients, simultaneous with their regular treatment (phototherapy, n = 11, and/or phenobarbital, n = 6). Patients received orlistat or placebo, each for 4-6 wk. Compared with placebo, orlistat increased fecal fat excretion (+333%) and fecal UCB excretion (+43%). Orlistat treatment significantly decreased plasma UCB concentration (-9%). In 7 of 16 patients, the decrease in plasma UCB levels was clinically relevant (>10%, mean 21%). In patients with a clinically relevant response, plasma UCB concentrations during orlistat were strongly, negatively correlated with fecal fat excretion (r = -0.93). Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake. In conclusion, orlistat treatment decreases plasma UCB concentrations, particularly in a subgroup of CN patients. Dietary fat intake may determine the responsiveness to orlistat treatment.


Asunto(s)
Bilirrubina/sangre , Síndrome de Crigler-Najjar/terapia , Lactonas/uso terapéutico , Fenobarbital/uso terapéutico , Fototerapia , Adolescente , Adulto , Fármacos Antiobesidad/efectos adversos , Fármacos Antiobesidad/uso terapéutico , Niño , Terapia Combinada , Síndrome de Crigler-Najjar/sangre , Síndrome de Crigler-Najjar/tratamiento farmacológico , Síndrome de Crigler-Najjar/metabolismo , Estudios Cruzados , Grasas de la Dieta/metabolismo , Método Doble Ciego , Quimioterapia Combinada , Ingestión de Alimentos , Heces/química , Femenino , Humanos , Lactonas/efectos adversos , Metabolismo de los Lípidos/efectos de los fármacos , Masculino , Persona de Mediana Edad , Orlistat , Cooperación del Paciente , Resultado del Tratamiento
3.
Pediatr Res ; 59(4 Pt 1): 506-12, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16549520

RESUMEN

Treatment with phototherapy or with the lipase inhibitor orlistat decreases plasma unconjugated bilirubin (UCB) concentrations in hyperbilirubinemic Gunn rats. We investigated the mechanism(s) underlying the effects of orlistat, phototherapy, and combined treatment, using steady-state 3H-UCB kinetics. After three weeks of treatment with orlistat (200 mg/kg chow), phototherapy (19 microW/cm2/nm) or combined treatment, tracer 3H-UCB was administered IV to treated and untreated (control) Gunn rats. Plasma samples and feces were collected every 12h for 60h, and bile for 30 min at 60h. The following results were obtained: 1) each treatment decreased plasma bilirubin levels compared with controls: orlistat- 19%, phototherapy-32%, combined treatment-53%; 2) plasma bilirubin concentrations were strongly, negatively correlated with fractional bilirubin turnover; 3) orlistat treatment induced net transmucosal excretion of UCB into the intestinal lumen, whereas phototherapy increased biliary UCB excretion rate; 4) all treatments profoundly increased the enterohepatic circulation of UCB derivatives, indicating enhanced metabolism by intestinal bacteria. In conclusion, orlistat and phototherapy lower plasma bilirubin concentrations in Gunn rats by increasing (net) intestinal influx of UCB, either by transmucosal excretion (orlistat), or increased biliary secretion (phototherapy). The mechanism of phototherapy and orlistat treatment involves increasing the availability of UCB in the intestinal lumen for fecal excretion and for metabolism by intestinal bacteria.


Asunto(s)
Inhibidores Enzimáticos/uso terapéutico , Hiperbilirrubinemia/terapia , Lactonas/uso terapéutico , Fototerapia , Animales , Bilis/química , Bilirrubina/metabolismo , Peso Corporal/efectos de los fármacos , Terapia Combinada , Ingestión de Alimentos/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Heces/química , Hiperbilirrubinemia/metabolismo , Lactonas/farmacología , Lipasa/antagonistas & inhibidores , Masculino , Orlistat , Ratas , Ratas Gunn , Tritio/metabolismo
4.
Hepatology ; 41(3): 526-34, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15726662

RESUMEN

We sought to develop an oral treatment for unconjugated hyperbilirubinemia. In the Gunn rat model of unconjugated hyperbilirubinemia, dietary supplementation with the lipase inhibitor orlistat (Orl) or with calcium phosphate (CaP) decreases plasma unconjugated bilirubin (UCB) levels. We determined whether Orl, CaP, or their combination is superior to phototherapy, the conventional treatment, and whether the effects of Orl and CaP are influenced by dietary fat content. Gunn rats were treated with Orl (200 mg/kg chow), CaP (20 g/kg chow), Orl + CaP, or continuous phototherapy (19 muW/cm(2)/nm) during a low-fat (LF) diet (13 energy%) or high-fat (HF) diet (35 energy%). Plasma UCB and fecal fat excretion were measured before, during, and/or at the end of treatment. Orl treatment for 2 weeks (HF diet) reduced plasma UCB concentrations similar to phototherapy (-34% and -28%, respectively); the combination of both was more effective than either treatment alone (-48%; P < .001). After 3 weeks of a HF diet, plasma UCB was 46% lower compared with the LF diet (P < .001). Plasma UCB concentrations were negatively correlated with fecal fat excretion (r = -0.96; P < .001). Irrespective of dietary fat content, 3 weeks of combined treatment (Orl + CaP) decreased plasma UCB by approximately 50% (P < .01) and was more effective than phototherapy (P < .05) at the intensity provided. In conclusion, plasma UCB concentrations in Gunn rats are negatively related to fecal fat excretion and dietary fat content. Orlistat is equally effective as phototherapy for the treatment of unconjugated hyperbilirubinemia in Gunn rats, and combined oral treatment with Orl + CaP is more effective than phototherapy. The present results support the feasibility of an efficient oral treatment of unconjugated hyperbilirubinemia.


Asunto(s)
Hiperbilirrubinemia/tratamiento farmacológico , Administración Oral , Animales , Bilirrubina/sangre , Calcio/metabolismo , Fosfatos de Calcio/uso terapéutico , Grasas de la Dieta/administración & dosificación , Heces/química , Hiperbilirrubinemia/sangre , Lactonas/uso terapéutico , Masculino , Orlistat , Fototerapia , Ratas , Ratas Gunn
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA